Nuwellis, Inc. Announces Closing of \$6.0 Million Registered Public Offering – Key Details for Investors
Summary of the Offering
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company specializing in solutions for patients with cardiorenal conditions, has successfully closed a registered public offering, raising approximately \$6.0 million in gross proceeds. The company issued 1,903,338 shares of common stock and pre-funded warrants to purchase 18,096,662 shares of common stock. Each of these securities was sold with accompanying Series C Warrants (up to 60,000,000 shares) and Series D Warrants (up to 20,000,000 shares) to purchase common stock.
Offering Structure & Pricing
- The public offering price per share (plus accompanying warrants) was \$0.30.
- The pre-funded warrants (plus accompanying warrants) were priced at \$0.2999 each, with an exercise price of \$0.0001 per warrant, making them immediately exercisable until exhausted.
- Both Series C and Series D Warrants have an exercise price of \$0.30 per share and will become exercisable for five years after stockholder approval and the effective date of a reverse stock split.
- The Series C Warrants include a one-time exercise price reset in the event of a reverse stock split, to the greater of: (i) 20% of the combined public offering price per share/warrant and (ii) 90% of the lowest daily volume weighted average price for the five trading days after the reverse split.
- Series D Warrants include a zero cash exercise option, allowing holders to receive shares without further cash payment, equivalent to a cash exercise.
Manager and Registration Details
- Ladenburg Thalmann & Co. Inc. served as the sole book-running manager.
- The securities were offered pursuant to an effective SEC registration statement (Form S-1, File No. 333-296198) and a subsequent registration statement (File No. 333-296518) filed under Rule 462(b).
Key Information for Shareholders
- Shareholder approval is required to allow the exercise of the Series C and Series D Warrants. This is a critical event that could impact the future share structure and valuation.
- The company may implement a reverse stock split. Both the exercise of warrants and their pricing could be significantly affected by this action.
- The inclusion of a reset mechanism in the Series C Warrants and a zero cash exercise option in the Series D Warrants introduces complexity and potential dilution for existing shareholders.
- The offering increases the number of shares and warrants outstanding, which could have dilutive effects on existing shareholders, especially if all warrants are eventually exercised.
About Nuwellis, Inc.
Nuwellis develops and commercializes technologies to support the management of complex cardiorenal conditions, focusing on safety, precision, and scalability. The company targets both acute and chronic care settings, aiming to enhance patient outcomes through innovative therapies and data-driven clinical decision-making.
Potential Impact on Share Price
- The successful closing of the offering strengthens the company’s cash position, which can be viewed as a positive for ongoing operations and R&D efforts.
- However, potential dilution from warrant exercises and an anticipated reverse stock split could lead to downward pressure on the share price.
- Price-sensitive elements: The necessity for stockholder approval for warrant exercisability and the mechanics of the reverse stock split and warrant resets are significant risks and opportunities for investors to monitor closely.
Forward-Looking Statements and Risks
The company cautions that forward-looking statements—including those about warrant exercisability, proceeds use, growth opportunities, and the impact of clinical and commercialization strategies—are subject to risks. These include the need for additional funding, commercialization success, product and market acceptance, and the execution of strategic initiatives. Investors are urged to review the risk factors detailed in Nuwellis’ SEC filings.
Contact Information
- Investor Relations: [email protected]
- Media Contact: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should perform their own due diligence and consult with qualified financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
